Evidence map›Paper›PMID 39529744›Full record

ArticleRSC advances2024

Synthesis of Cu/Mn/Ce polymetallic oxide catalysts and catalytic ozone treatment of wastewater.

Jinlong Zhong, Xue Feng Mao, Guanyu Wang, Heng Li, Junfang Li, Sijian Qu, Jianwei Zhao

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinlong ZhongChina Coal Research Institute Beijing 100013 China 61865298@qq.com +86-10-84262941.ORCID https://orcid.org/0009-0002-5541-8239
Xue Feng MaoChina Coal Research Institute Beijing 100013 China 61865298@qq.com +86-10-84262941.
Guanyu WangChina Coal Research Institute Corporation Ltd. Beijing 100013 China.
Heng LiChina Coal Research Institute Corporation Ltd. Beijing 100013 China.
Junfang LiChina Coal Research Institute Corporation Ltd. Beijing 100013 China.
Sijian QuChina Coal Research Institute Beijing 100013 China 61865298@qq.com +86-10-84262941.
Jianwei ZhaoShenzhen HUASUAN Technology Co., Ltd Beijing 100013 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-homogeneous ozone-catalyzed oxidation technology is one of the effective ways of treating wastewater, the core of which lies in the development of efficient ozone oxidation catalysts. This work proposes the design and synthesis of an efficient Cu/Mn/Ce multi-metal composite oxide catalyst by metal salt precursor mixing-direct granulation. The effect of metal doping on the catalyst properties was compared using Density function theory (DFT) calculations, and the Cu/Mn/Ce co-doping showed significant charge accumulation effect with a low ozonolysis energy barrier, which is more favorable for the generation of reactive oxygen species. The successful loading of the main active metal components, such as Mn, Cu, and Ce, was clarified by systematic characterization by X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS) and Brunauer-Emmett-Teller's test (BET), and the chemical oxygen demand (COD) removal could reach more than 60% for the simulated wastewater. The electron paramagnetic resonance (EPR) characterization clarified that the degradation of organic pollutants was mainly dominated by the combination of single-linear oxygen and superoxide radicals in the catalytic process, and the possible catalytic oxidation mechanism was proposed. This work advances the development of non-homogeneous ozone oxidation technology.

Identifiers

PMID39529744
PMCPMC11551843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.